Vertex’s CEO was an AI skeptic. But not anymore.

Vertex Pharmaceuticals chief Reshma Kewalramani said AI could reduce the time spent on drug-approval paperwork from months to ...
Fierce Pharma

Vertex touts Journavx launch metrics after novel pain med came up just short of expectations in Q3

One key figure, however, indicates otherwise as sales for Journavx were at $20 million for the period, coming up $3 million ...

Vertex Pharmaceuticals: JOURNAVX Prescription Demand And Povetacicept Developments Warrant "Strong Buy"

Vertex Pharmaceuticals (VRTX) is rated as a "Strong Buy" due to robust revenue growth and multiple expansion opportunities ...
Stockhead on MSN

Who’s Who with Vertex Minerals: Ramping up on a high-grade gold Reward

Tylah Tully looks at Vertex Minerals and its growing high-grade gold production in the latest episode of Stockhead's Who’s ...
StockStory.org on MSN

5 Insightful Analyst Questions From Vertex Pharmaceuticals’s Q3 Earnings Call

Vertex Pharmaceuticals’ third quarter was marked by steady double-digit revenue growth, yet the market responded negatively ...
TipRanks on MSN

Vertex Minerals Updates on Reward Gold Mine Operations Amidst Challenges

Vertex Minerals Ltd. ( ($AU:VTX) ) has issued an update. Vertex Minerals Ltd. has announced an update on its Reward Gold Mine operations, ...
Which

How much will I need to retire?

When you stop working is up to you, but whether you can afford the retirement lifestyle you want all comes down to how much you've managed to save. In a 2025 survey carried out by Which?, 49% of ...
Wall Street Journal

Hang Seng Index HSI

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International stock ...